|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
De Vita F, Di Martino N, Fabozzi A,
Laterza MM, Ventriglia J, Savastano B, Petrillo A, Gambardella V,
Sforza V, Marano L, et al: Clinical management of advanced gastric
cancer: The role of new molecular drugs. World J Gastroenterol.
20:14537–14558. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Singh UP, Venkataraman C, Singh R and
Lillard JW Jr: CXCR3 axis: Role in inflammatory bowel disease and
its therapeutic implication. Endocr Metab Immune Disord Drug
Targets. 7:111–123. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lacotte S, Brun S, Muller S and Dumortier
H: CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci.
1173:310–317. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Billottet C, Quemener C and Bikfalvi A:
CXCR3, a double-edged sword in tumor progression and angiogenesis.
Biochim Biophys Acta. 1836:287–295. 2013.PubMed/NCBI
|
|
6
|
Lo BK, Yu M, Zloty D, Cowan B, Shapiro J
and McElwee KJ: CXCR3/ligands are significantly involved in the
tumorigenesis of basal cell carcinomas. Am J Pathol. 176:2435–2446.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu Z, Han X, Yan J, Pan Y, Gong J, Di J,
Cheng Z, Jin Z, Wang Z, Zheng Q, et al: The prognostic significance
of chemokine receptor CXCR3 expression in colorectal carcinoma.
Biomed Pharmacother. 66:373–377. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ma B, Khazali A and Wells A: CXCR3 in
carcinoma progression. Histol Histopathol. 30:781–792. 2015.
|
|
9
|
Furuya M, Yoneyama T, Miyagi E, Tanaka R,
Nagahama K, Miyagi Y, Nagashima Y, Hirahara F, Inayama Y and Aoki
I: Differential expression patterns of CXCR3 variants and
corresponding CXC chemokines in clear cell ovarian cancers and
endometriosis. Gynecol Oncol. 122:648–655. 2011. View Article : Google Scholar
|
|
10
|
Shen D and Cao X: Potential role of CXCR3
in proliferation and invasion of prostate cancer cells. Int J Clin
Exp Pathol. 8:8091–8098. 2015.
|
|
11
|
Wu Q, Dhir R and Wells A: Altered CXCR3
isoform expression regulates prostate cancer cell migration and
invasion. Mol Cancer. 11:32012. View Article : Google Scholar
|
|
12
|
Hu M, Li K, Maskey N, Xu Z, Yu F, Peng C,
Li Y and Yang G: Overexpression of the chemokine receptor CXCR3 and
its correlation with favorable prognosis in gastric cancer. Hum
Pathol. 46:1872–1880. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Salazar N, Castellan M, Shirodkar SS and
Lokeshwar BL: Chemokines and chemokine receptors as promoters of
prostate cancer growth and progression. Crit Rev Eukaryot Gene
Expr. 23:77–91. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Van Raemdonck K, Van den Steen PE, Liekens
S, Van Damme J and Struyf S: CXCR3 ligands in disease and therapy.
Cytokine Growth Factor Rev. 26:311–327. 2015. View Article : Google Scholar
|
|
15
|
Murakami T, Kawada K, Iwamoto M, Akagami
M, Hida K, Nakanishi Y, Kanda K, Kawada M, Seno H, Taketo MM, et
al: The role of CXCR3 and CXCR4 in colorectal cancer metastasis.
Int J Cancer. 132:276–287. 2013. View Article : Google Scholar
|
|
16
|
Goldberg-Bittman L, Neumark E, Sagi-Assif
O, Azenshtein E, Meshel T, Witz IP and Ben-Baruch A: The expression
of the chemokine receptor CXCR3 and its ligand, CXCL10, in human
breast adenocarcinoma cell lines. Immunol Lett. 92:171–178. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ling CC, Ng KT, Shao Y, Geng W, Xiao JW,
Liu H, Li CX, Liu XB, Ma YY, Yeung WH, et al: Post-transplant
endothelial progenitor cell mobilization via CXCL10/CXCR3 signaling
promotes liver tumor growth. J Hepatol. 60:103–109. 2014.
View Article : Google Scholar
|
|
18
|
Datta D, Banerjee P, Gasser M,
Waaga-Gasser AM and Pal S: CXCR3-B can mediate growth-inhibitory
signals in human renal cancer cells by down-regulating the
expression of heme oxygenase-1. J Biol Chem. 285:36842–36848. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gacci M, Serni S, Lapini A, Vittori G,
Alessandrini M, Nesi G, Palli D and Carini M: CXCR3-B expression
correlates with tumor necrosis extension in renal cell carcinoma. J
Urol. 181:843–848. 2009. View Article : Google Scholar
|
|
20
|
Pu Y, Li S, Zhang C, Bao Z, Yang Z and Sun
L: High expression of CXCR3 is an independent prognostic factor in
glioblastoma patients that promotes an invasive phenotype. J
Neurooncol. 122:43–51. 2015. View Article : Google Scholar
|
|
21
|
Ma X, Norsworthy K, Kundu N, Rodgers WH,
Gimotty PA, Goloubeva O, Lipsky M, Li Y, Holt D and Fulton A: CXCR3
expression is associated with poor survival in breast cancer and
promotes metastasis in a murine model. Mol Cancer Ther. 8:490–498.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pradelli E, Karimdjee-Soilihi B, Michiels
JF, Ricci JE, Millet MA, Vandenbos F, Sullivan TJ, Collins TL,
Johnson MG, Medina JC, et al: Antagonism of chemokine receptor
CXCR3 inhibits osteosarcoma metastasis to lungs. Int J Cancer.
125:2586–2594. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Utsumi T, Suyama T, Imamura Y, Fuse M,
Sakamoto S, Nihei N, Ueda T, Suzuki H, Seki N and Ichikawa T: The
association of CXCR3 and renal cell carcinoma metastasis. J Urol.
192:567–574. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Anestakis D, Petanidis S, Kalyvas S, Nday
CM, Tsave O, Kioseoglou E and Salifoglou A: Mechanisms and
applications of interleukins in cancer immunotherapy. Int J Mol
Sci. 16:1691–1710. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lippitz BE: Cytokine patterns in patients
with cancer: A systematic review. Lancet Oncol. 14:e218–e228. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang G, Ye Y, Zhang X and Song J:
Bradykinin stimulates IL-6 production and cell invasion in
colorectal cancer cells. Oncol Rep. 32:1709–1714. 2014.PubMed/NCBI
|
|
27
|
Dehai C, Bo P, Qiang T, Lihua S, Fang L,
Shi J, Jingyan C, Yan Y, Guangbin W and Zhenjun Y: Enhanced
invasion of lung adenocarcinoma cells after co-culture with
THP-1-derived macrophages via the induction of EMT by IL-6. Immunol
Lett. 160:1–10. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jenkins MH, Brinckerhoff CE and Mullins
DW: CXCR3 signaling in BRAFWT melanoma increases IL-8 expression
and tumorigenicity. PLoS One. 10:e01211402015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Burotto M, Chiou VL, Lee JM and Kohn EC:
The MAPK pathway across different malignancies: A new perspective.
Cancer. 120:3446–3456. 2014. View Article : Google Scholar : PubMed/NCBI
|
